Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RITUXERA Trial
2023-506638-59-01Phase 4Authorised
- Sponsor
- UZ Leuven
- Start
- Nov 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised trial of rituximab in rheumatoid arthritis (RA) (2 arms), sponsored by UZ Leuven. Primary endpoint: Disease impact over 104 weeks. Planned start Nov 2023; status: authorised.
02
Drugs
rituximab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2023-506638-59-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-506638-59-01.